Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine. - Wikidata - wikimedia - TriplyDB

Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine.

Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine.

http://www.wikidata.org/entity/Q37623293

about

Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells Activity of peroxisomal enzymes, and levels of polyamines in LPA-transgenic mice on two different diets.Albumin-derived advanced glycation end-products trigger the disruption of the vascular endothelial cadherin complex in cultured human and murine endothelial cells Genetic risk factors in Alzheimer's disease The role of calcium-independent phospholipase A2 in cardiolipin remodeling in the spontaneously hypertensive heart failure rat heart Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling.Effects of a new advanced glycation inhibitor, LR-90, on mitigating arterial stiffening and improving arterial elasticity and compliance in a diabetic rat model: aortic impedance analysis.Intervening in atherogenesis: lessons from diabetes.Carbonylation of myosin heavy chains in rat heart during diabetes.Advanced glycation end products of bovine serum albumin-induced endothelial-to-mesenchymal transition in cultured human and monkey endothelial cells via protein kinase B signaling cascades.A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys Caloric restriction mimetics: metabolic interventions.Aminoguanidine prevents age-related aortic stiffening in Fisher 344 rats: aortic impedance analysis.Aminoguanidine prevents age-related deterioration in left ventricular-arterial coupling in Fisher 344 rats.Reduced acute vascular injury and atherosclerosis in hyperlipidemic mice transgenic for lysozyme.New-onset diabetes and glucose regulation are significant determinants of left ventricular hypertrophy in renal transplant recipients.The Effect of Systemic Delivery of Aminoguanidine versus Doxycycline on the Resorptive Phase of Alveolar Bone Following modified Widman Flap in Diabetic Rats: A Histopathological and Scanning Electron Microscope (SEM) study Novel therapeutic strategies for reducing arterial stiffness Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats.Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression.Glycated collagen cross-linking alters cardiac mechanics in volume-overload hypertrophy Co-localisation of advanced glycation end products and D-β-aspartic acid-containing proteins in gelatinous drop-like corneal dystrophy.Low-molecular weight advanced glycation end products: markers of tissue AGE accumulation and more?Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan.Identifying advanced glycation end products as a major source of oxidants in aging: implications for the management and/or prevention of reduced renal function in elderly persons Hippocampal calcium dysregulation at the nexus of diabetes and brain aging.Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products.Aging increases oxidative stress and renal expression of oxidant and antioxidant enzymes that are associated with an increased trend in systolic blood pressure.Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms Reactive metabolites and AGE/RAGE-mediated cellular dysfunction affect the aging process: a mini-review.Kidney aging--inevitable or preventable?Role of advanced glycation endproducts and potential therapeutic interventions in dialysis patients.Molecular strategies to prevent, inhibit, and degrade advanced glycoxidation and advanced lipoxidation end products.Advanced glycation end product accumulation: a new enemy to target in chronic kidney disease?Advanced Glycation End Products, Inflammation, and Chronic Metabolic Diseases: Links in a Chain?Amelioration of oxidant stress by the defensin lysozyme.Renal accumulation of pentosidine in non-diabetic proteinuria-induced renal damage in rats.Effect of high-fat diet on metabolic indices, cognition, and neuronal physiology in aging F344 rats.Pharmacological prevention of cardiovascular aging--targeting the Maillard reaction

P2860

Q24563997-3ADE68FC-BC40-4056-9887-750E0B451F62 Q24813990-407E3C1D-BC79-48FC-86A8-14A94C4D5D7D Q28362386-CD731D38-05DD-4214-9119-022D6FE00726 Q33588353-3001F99C-6F55-4FE9-BD8B-A340C1D91F31 Q33634137-BE564FA2-7ED9-4C2E-B2F0-472420762342 Q33711306-544F6393-F200-4F1A-9E8A-28BFC96703BA Q33746869-3F38EE18-9F19-44EF-8F04-2A39397E633F Q34099570-151DB4E0-DCAE-4950-BB1E-9B814A7B2273 Q34334665-5C25A6CD-199C-4814-97E0-27FA5698D0E3 Q34410712-99927584-7E98-4C1B-8296-6F8FC972AA4A Q34652366-0A7E89E3-E2A6-4284-B624-2FBBB9330D58 Q34712074-8BBBADCE-556A-4CD4-8542-449829A3662F Q35045662-AF2D1CED-66E7-4419-BCB8-2BE2CF9F49D2 Q35047489-82AE9A06-243B-47BF-AC0D-F16517D31EAA Q35221896-F3584D5E-2BF1-40F5-B2F9-BEF28C213B42 Q35508630-747455EA-2307-43A5-AAE0-BE482699EBEF Q35518968-05117E1E-5E1C-46C0-9C83-1A9D30D743BC Q35546271-42F2B560-925D-4024-A9A1-5972AC823F1D Q35546284-60CCE064-B848-4915-9C3C-497341F33969 Q35805813-41380A0E-0537-40DF-A821-9ACE07DE85D1 Q35855642-D9D3240C-118B-44AF-BFCA-9FADA9BD6228 Q35887541-479703F2-4480-4791-B00E-6FCA44438899 Q36115597-5F313B95-CC7B-450F-AD59-F57C8311999A Q36203996-33D87558-AB75-4130-A2E8-04DF50851181 Q36778201-460F8856-894B-43CB-8AE7-9195591C63C1 Q37214116-0120B852-1138-4DA9-A0AC-2FFF3A8140B4 Q37337291-56CBF60D-B3A5-4869-85DD-19AB8CB08198 Q37364608-9C444AAF-074D-4F00-A581-D88C5A624B3E Q37390266-71701190-874A-46D0-AEEA-EC81370C64AC Q37636453-D194CBD2-CD33-44CC-8686-83281C8AD0B6 Q37801791-D4FB1B9E-8CF0-4CFB-8473-60E92AA9982F Q37913979-5A63A263-42FF-4A0B-AEA1-2AA837FC862A Q38006722-651BF873-BDEC-4EFB-8DD2-A4C565780D59 Q38096444-88D30EBA-78FE-4FF9-9538-85985F2A8B59 Q38243632-1DE85CCA-DC76-4C48-B0EA-777FA7C724B2 Q38254631-4AF4DC24-7904-43B1-BCB5-8B7339DFFE3A Q40346041-803474E7-A841-4CDB-8599-BEC740A8A9B7 Q40414133-55394ADA-F5FE-4C8D-9E83-DAC3D1DC1073 Q41880535-0A62CA57-06D7-41EB-94D1-1423E322CC3D Q42126940-3EB324F9-EA85-4054-A416-3024E01A9895

P2860

Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguanidine.

http://www.wikidata.org/entity/Q37623293

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on April 1996

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Prevention of cardiovascular a ...... tion inhibitor aminoguanidine.

@en

Prevention of cardiovascular a ...... tion inhibitor aminoguanidine.

@nl

type

label

Prevention of cardiovascular a ...... tion inhibitor aminoguanidine.

@en

Prevention of cardiovascular a ...... tion inhibitor aminoguanidine.

@nl

prefLabel

Prevention of cardiovascular a ...... tion inhibitor aminoguanidine.

@en

Prevention of cardiovascular a ...... tion inhibitor aminoguanidine.

@nl

P1433

Q37623293-E3782BF6-4C62-41AA-8F2F-5227DFAB0731

P1476

Q37623293-2330A45C-CA4A-4422-A87C-FF4630CF63D9

P2093

Q37623293-0AFFA2B1-15BA-4ECB-99D6-108800D6BBDB

Q37623293-2114C6FB-4177-4618-B849-CBDE9F462F13

Q37623293-34637313-4D12-40E1-8719-01C49692F702

Q37623293-5FA75936-F745-4110-894E-ED0C1A1A4861

Q37623293-81B8B01B-7A37-47E3-8F9F-508037F19EDC

Q37623293-8B28F93B-7419-4508-BED7-3625389C8F87

Q37623293-BCD4871E-7181-4B70-B8B0-9CB18988D2CD

P2860

Q37623293-0675E3BF-34BD-4550-B411-DDCB9068C448

Q37623293-0CE29368-1A8B-4AEE-A318-64CDB500B188

Q37623293-0EEECDCC-047E-4224-B2B9-1AD6E73EECD4

Q37623293-18B58AAC-E07B-4118-A94C-DB890FA17AAD

Q37623293-1E12C8AE-C123-4CE7-9D52-B6020AA15E60

Q37623293-1E513E99-631A-4E43-BC4C-5A0C8764A64A

Q37623293-20D95ADE-C24E-475E-9E3E-C55D425C5545

Q37623293-21103C4B-38DA-49E4-AD64-A18264729A0C

Q37623293-2418F2DA-17EB-4E77-8C57-8EA65F748B7D

Q37623293-26E71863-9838-4D04-9463-A94FED7DAD29

P304

Q37623293-B2ECA380-B95B-43A3-B28B-440068DDBF9A

P31

Q37623293-18974407-97C8-40AB-B17D-6940BCA3705D

P356

Q37623293-598D8DC2-F190-40FF-BCCF-5DC6398F1C23

P407

Q37623293-D0AF64A1-2C82-42DF-9AC8-D903BB76F6A8

P433

Q37623293-C4EC7D67-B298-4EEF-98E1-3278D624178D

P478

Q37623293-4B467F59-03E1-4266-8268-636240384888

P50

Q37623293-2A3CFF85-DF82-46F0-B682-E9B320C1B380

P577

Q37623293-4DB73193-E102-4804-9C9B-275F98E181B8

P5875

Q37623293-B16DDC1B-A730-4A25-BAEF-CA1D0950ED2F

P698

Q37623293-6023AD32-8ECB-4E9C-A6E3-85DD5A3C92D8

P921

Q37623293-3510A96F-1278-461B-A204-2D91E387728E

Q37623293-fe231b29-2857-4065-b30c-394fafeea1ca

P932

Q37623293-3B630F9D-63F8-4592-A1CB-CEBA7128671A

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Prevention of cardiovascular a ...... ation inhibitor aminoguanidine

@en

P2093

C Liu

http://www.w3.org/2001/XMLSchema#string

H Fuh

http://www.w3.org/2001/XMLSchema#string

H Vlassara

http://www.w3.org/2001/XMLSchema#string

J Basgen

http://www.w3.org/2001/XMLSchema#string

M Steffes

http://www.w3.org/2001/XMLSchema#string

R Bucala

http://www.w3.org/2001/XMLSchema#string

Y M Li

http://www.w3.org/2001/XMLSchema#string

P2860

The pathogenesis of atherosclerosis: a perspective for the 1990s

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications.

Age-dependent glomerular damage in the rat. Dissociation between glomerular injury and both glomerular hypertension and hypertrophy. Male gender as a primary risk factor.

Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes.

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking.

Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat.

Changes in renal function with aging. Implications for treatment.

Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats

Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor

Exogenous advanced glycosylation end products induce complex vascular dysfunction in normal animals: a model for diabetic and aging complications.

P304

3902-3907

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.93.9.3902

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P50

Thomas M Donnelly

P577

1996-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14567548

http://www.w3.org/2001/XMLSchema#string

P698

8632987

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

39457

http://www.w3.org/2001/XMLSchema#string